Bioinformation Therapy for Breast Cancer

Status Completed

Clinical Trial Summary

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable breast cancer.

Clinical Trial Description

By enrolling patients with unresectable breast cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03240224
Study type	Interventional
Source	Fuda Cancer Hospital, Guangzhou
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	September 2, 2017
Completion date	September 2, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04653740` - Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer	N/A
Completed	`NCT02091960` - A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer	Phase 2
Recruiting	`NCT05156619` - Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
Recruiting	`NCT05173103` - Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
Withdrawn	`NCT05191004` - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC	Phase 1/Phase 2
Completed	`NCT00754325` - Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor	Phase 2
Recruiting	`NCT04953377` - PFMT Educational Intervention for Patients With Advancer Breast Cancer	N/A
Recruiting	`NCT06193525` - FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test	Phase 2
Completed	`NCT03312738` - A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor	Phase 2
Active, not recruiting	`NCT05063786` - Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)	Phase 3
Recruiting	`NCT05655598` - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer	Phase 1
Active, not recruiting	`NCT02499146` - Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer	Phase 1
Completed	`NCT00445458` - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT04456855` - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Completed	`NCT04408118` - First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC	Phase 2
Recruiting	`NCT04222413` - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	Phase 1
Completed	`NCT03205761` - Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer	Phase 2
Withdrawn	`NCT04316169` - Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer	Phase 1
Completed	`NCT00546104` - Phase II Dasatinib Study in Advanced Breast Cancer	Phase 2
Completed	`NCT00387907` - Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer	Phase 2